You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: January 2022 to February 2026

AbstractFullPdf
Jan 202233833995
Feb 2022862879237
Mar 2022417423164
Apr 2022329341181
May 2022212219141
Jun 202227628390
Jul 202249449985
Aug 202251051458
Sep 202249449660
Oct 202249850549
Nov 202247947962
Dec 202250651260
Jan 202346846837
Feb 202346046155
Mar 202347948473
Apr 202347347362
May 202337937958
Jun 202333933935
Jul 202334634749
Aug 202332932936
Sep 202333733844
Oct 202330430435
Nov 202325125149
Dec 202326526658
Jan 202414414434
Feb 202418418452
Mar 202424724761
Apr 202419319475
May 202422122281
Jun 202419819967
Jul 202420921259
Aug 2024208205101
Sep 202416116241
Oct 202417717757
Nov 202412512733
Dec 202418019174
Jan 202514514537
Feb 2025929240
Mar 202515615870
Apr 202517117274
May 202514114464
Jun 2025909150
Jul 2025110
Aug 2025110
Feb 2026110
Total12890129972943